CELULARITY INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.205 USD | -1.38% |
|
-1.38% | +29.55% |
Presenter SpeechRobert Hariri (Executives)Hello, everybody. I'm Dr. Bob Hariri, I'm the Founde...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohnâs disease.
| 1st Jan change | Capi. | |
|---|---|---|
| +29.55% | 69.81M | |
| +18.15% | 124B | |
| +18.02% | 112B | |
| +5.07% | 22.94B | |
| -12.75% | 22.22B | |
| -9.86% | 17.02B | |
| -14.97% | 16.88B | |
| -39.94% | 16.87B | |
| +2.80% | 13.63B | |
| +27.39% | 11.61B |
- Stock Market
- Equities
- CELU Stock
- News Celularity Inc.
- Transcript : Celularity Inc. - Analyst/Investor Day
